Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.09.14.20191759: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: They have provided written informed consent for the use of their samples for research.
IRB: Ethics approval was given by the French Ethics Committee CPP-lle-de-France 6 (ID RCB: 2020-A00256-33 and ID RCB: 2020-A00280-39) and the French National Data Protection Commission (approval #920102).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Briefly, in each well of 96-wells microplates previously coated with anti-SARS-CoV-2 N-antibodies, 50 μl of a solution containing a biotinylated anti-SARS-CoV-2 N antibodies and 50 μl of sera were added. anti-S…SciScore for 10.1101/2020.09.14.20191759: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: They have provided written informed consent for the use of their samples for research.
IRB: Ethics approval was given by the French Ethics Committee CPP-lle-de-France 6 (ID RCB: 2020-A00256-33 and ID RCB: 2020-A00280-39) and the French National Data Protection Commission (approval #920102).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Briefly, in each well of 96-wells microplates previously coated with anti-SARS-CoV-2 N-antibodies, 50 μl of a solution containing a biotinylated anti-SARS-CoV-2 N antibodies and 50 μl of sera were added. anti-SARS-CoV-2suggested: Noneanti-SARS-CoV-2 Nsuggested: NoneSoftware and Algorithms Sentences Resources Detection of anti-SARS-CoV-2 nucleocapsid IgG: For a subset of 85 sera, corresponding to 80 patients (ICU patients: n = 21, ward patients: n = 36 and outpatients: n = 36), we performed a chemiluminescent microparticle immunoassay detecting anti-N immunoglobulins G (Architect SARS-CoV-2 IG Assay, Abbott). Abbottsuggested: (Abbott, RRID:SCR_010477)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A limitation of this first N-antigenemia evaluation for COVID-19 diagnosis is the high proportions of ICU and ward patients. N-antigenemia decrease seems to occur earlier in outpatients, but have to be confirmed in larger cohorts. This innovative marker opens new perspectives for diagnostic, such as rapid antigen blood test and combined ELISA assays, detecting both antigens and antibodies. This could provide a valuable new option for COVID-19 diagnosis, only requiring a blood draw, scalable in all clinical laboratories and high throughput analyzers.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04262921 Recruiting French COVID Cohort NCT04259892 Recruiting Viral Excretion in Contact Subjects at High/Moderate Risk of… NCT04259892 Recruiting Viral Excretion in Contact Subjects at High/Moderate Risk of… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
